Drug Profile
Rasburicase biosimilar - Jilin Xiuzheng Pharmaceutical New Medicine Development
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Hangzhou Biodoor Biotechnology
- Developer JILIN XIUZHENG PHARMACEUTICAL
- Class Antigouts; Oxidoreductases
- Mechanism of Action Urate oxidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hyperuricaemia
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for clinical-Phase-Unknown development in Hyperuricaemia in China (IV)
- 18 Feb 2016 Clinical trials in Hyperuricaemia in China (IV)